SAGE - Sage Therapeutics mixed Q4 earnings; initiates FY23 outlook

• Sage Therapeutics press release ( NASDAQ: SAGE ): Q4 GAAP EPS of -$2.47 misses by $0.08 .
• Revenue of $2.9M (+81.3% Y/Y) beats by $0.96M .
• Cash, cash equivalents and marketable securities as of December 31, 2022 were $1.3 billion compared to $1.4 billion at September 30, 2022.
• Guidance: Based upon the company's current operating plan, Sage anticipates that its existing cash, cash equivalents and marketable securities, anticipated funding from ongoing collaborations, and potential revenue, will support its operations into 2025.?
• This includes the potential to achieve milestones totaling $225.0 million from Biogen related to first commercial sales of zuranolone in MDD and PPD in the U.S., if approved.
• The Company anticipates R&D and SG&A spending to increase as it prepares for the potential launch of zuranolone and advances planned and ongoing studies for SAGE-718 and SAGE-324.?

For further details see: